Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIALTO: 177Lu-Dotatate Every 8 vs 16 Weeks in Advanced Midgut NETs
NCT06878664Phase 3Recruiting
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Jun 2025
- Primary completion
- Jan 2029
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by Spanish Group of Neuroendocrine Tumors. Started Jun 2025; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06878664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878664.